Opendata, web and dolomites

GlyCoCan SIGNED

Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlyCoCan project word cloud

Explore the words cloud of the GlyCoCan project. It provides you a very rough idea of what is the project "GlyCoCan" about.

individual    immunology    reduce    incidence    generation    tackling    esr    worldwide    colleagues    treatment    successful    giving    screening    disciplinary    immense    training    pave    biomarkers    principally    regard    700    perspective    techniques    building    invasive    collaborations    relationship    gmp    regulations    sensitivity    glycobiology    efficient    underlying    proteomics    cancer    annual    lack    ich    detection    network    poorly    therapeutic    antigens    inter    function    academic    crc    million    biomarker    diagnostic    oncology    substantially    iso9001    productive    unmet    diseases    carbohydrate    guidelines    suggested    substantial    stages    structure    nov    young    internationally    population    glyco    careers    esrs    approximately    teaching    colorectal    screenings    mortality    2012    burden    prognostic    glycosylation    glycans    molecular    scientific    transfer    el    mechanisms    discovery    glycocan    molecules    industrial    specificity    biopharma   

Project "GlyCoCan" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://glycocan.eu/
 Total cost 3˙297˙697 €
 EC max contribution 3˙293˙890 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2015
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 628˙470.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 525˙751.00
3    NOVA ID FCT - ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT PT (CAPARICA) participant 476˙712.00
4    GENOS DOO ZA VJESTACENJE I ANALIZU HR (OSIJEK) participant 371˙641.00
5    LUDGER LIMITED UK (ABINGDON) participant 273˙287.00
6    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 258˙061.00
7    STICHTING VU NL (AMSTERDAM) participant 255˙374.00
8    STICHTING VUMC NL (AMSTERDAM) participant 255˙374.00
9    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 249˙216.00
10    FACULDADE DE CIENCIAS MEDICAS DA UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) participant 0.00
11    DC4U NL (BREUKELEN) partner 0.00
12    INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA PT (OEIRAS) partner 0.00
13    INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE PT (PORTO) partner 0.00
14    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) partner 0.00
15    Postdoc Career Development Forum BV NL (Utrecht) partner 0.00
16    ROCHE DIAGNOSTICS GMBH DE (MANNHEIM) partner 0.00
17    UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN DE (Lübeck) partner 0.00

Map

 Project objective

Colorectal cancer (CRC) is a major worldwide cancer burden with about 1.4 million cases in 2012 and an annual mortality of approximately 700,000. Early detection is crucial as treatment is most efficient in early stages where population based screenings could substantially reduce incidence and mortality. Current screening techniques are invasive or lack sensitivity and specificity. Moreover, the molecular mechanisms leading to the formation of different antigens suggested as CRC biomarkers and potential therapeutic targets are poorly understood, especially with regard to carbohydrate-based molecules, such as glycans. Enhancing our understanding of the structure-function relationship of glycosylation in CRC could lead to the discovery of improved diagnostic and prognostic biomarkers and pave the way for nov-el therapeutic targets. Building on an established network of analysts with many years of experience in (glyco)proteomics and biomarker research, in collaboration with colleagues in the field of glycobiology and glyco-immunology, GlyCoCan will develop new methods, and use current state of the art methods, to investigate the role of glycosylation in many different aspects of CRC. The GlyCoCan multi-disciplinary network will principally be a training programme with a substantial industrial focus on technology transfer and teaching of internationally adopted biopharma regulations (GMP, ISO9001, ICH guidelines). The underlying specific research objectives will be addressed within individual ESR projects, giving rise to a generation of ESRs whose main focus is investigating and tackling the challenges of the role of glycosylation within CRC and other diseases. The network will address the currently unmet need for glycosylation researchers with an inter-disciplinary perspective to fully exploit the immense potential of the young scientific field of glyco-oncology and to set them on a path to successful and productive careers in academic and industrial collaborations.

 Deliverables

List of deliverables.
Completion of theses Websites, patent fillings, videos etc. 2020-04-06 09:29:28
Website established Websites, patent fillings, videos etc. 2020-04-06 09:29:27

Take a look to the deliverables list in detail:  detailed list of GlyCoCan deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Zejian Zhang, Manfred Wuhrer, Stephanie Holst
Serum sialylation changes in cancer
published pages: 139-160, ISSN: 0282-0080, DOI: 10.1007/s10719-018-9820-0
Glycoconjugate Journal 35/2 2020-04-06
2018 Athanasios Blanas, Neha M. Sahasrabudhe, Ernesto Rodríguez, Yvette van Kooyk, Sandra J. van Vliet
Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00039
Frontiers in Oncology 8 2020-04-06
2018 Mylène A. Carrascal, Catarina Talina, Paula Borralho, A. Gonçalo Mineiro, Ana Raquel Henriques, Cláudia Pen, Manuela Martins, Sofia Braga, Robert Sackstein, Paula A. Videira
Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue
published pages: , ISSN: 1471-2407, DOI: 10.1186/s12885-018-4410-x
BMC Cancer 18/1 2020-04-06
2018 Inês Gomes Ferreira, Michela Pucci, Giulia Venturi, Nadia Malagolini, Mariella Chiricolo and Fabio Dall’Olio
Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling
published pages: 580, ISSN: 1422-0067, DOI: 10.3390/ijms19020580
International Journal of Molecular Sciences 19/2 2020-04-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCOCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCOCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

NanoCarb (2018)

Glyco-Nanoparticles for Applications in Advance Nanomedicine

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More